Novel large yellow tea polysaccharide and application thereof in preparation of antihypertensive pharmaceutical preparation

The new Huangda Tea polysaccharide LYTP 2-2 prepared through ultrafiltration and chromatography regulates the RAAS system, solves the problems of toxic and side effects of existing anti-hypertensive drugs, and achieves the effect of effectively lowering blood pressure and improving the damage of hypertensive target organs. Significant pharmacological effects and safety.

CN118930676APending Publication Date: 2024-11-12FUGONG YUANLUODAPULUO TEA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411199497.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing antihypertensive drugs have toxic side effects that some patients cannot tolerate, and lack the natural active ingredients of green, efficient, multi-link and multi-target intervention in hypertension. The literature on Huangda Tea polysaccharide in the treatment of hypertension and related target organ damage has not been found. See report.

Method used

Ultrafiltration separation, DEAE-Sepharose Fast Flow ion exchange chromatography and SuperdexTM200 gel filtration chromatography technology were used to prepare a new Huangda Tea high-active polysaccharide LYTP 2-2 with a specific composition, which reduces blood pressure and relieves hypertension by regulating RAAS. damage.

Benefits of technology

The new yellow tea polysaccharide LYTP 2-2 has good ACE inhibitory activity, can effectively reduce systolic blood pressure, diastolic blood pressure and left ventricular mass index, improve aortic and glomerular damage, and long-term use has no toxic side effects on the body, and has broad development Application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930676A_ABST
    Figure CN118930676A_ABST
Patent Text Reader

Abstract

The invention discloses a novel large yellow tea polysaccharide and an application thereof in preparation of a blood pressure lowering pharmaceutical preparation, the novel large yellow tea polysaccharide is briefly denoted as LYTP 2-2, the total sugar content is 89.75%, the monosaccharide composition and the molar ratio of mannose to rhamnose to galacturonic acid to glucose to galactose to arabinose are 1.844: 2.898: 2.4: 29.98: 10.438: 1, and the relative molecular mass is 2.0898 * 10 < 4 > Da. Efficacy experiments show that the Huangdan tea polysaccharide LYTP 2-2 has good ACE inhibitory activity, and can significantly reduce systolic pressure and diastolic pressure and improve left ventricular hypertrophy, thoracic aorta thickening and kidney injury by regulating RAAS in a two-kidney one-clip hypertension rat body. The novel large yellow tea polysaccharide LYTP 2-2 is clear in composition and remarkable in effect, and has wide development and application prospects in the research aspect of preparing medicine preparations for reducing blood pressure and improving hypertension target organ injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine preparation, and specifically relates to a novel yellow tea polysaccharide and application thereof in the preparation of a blood pressure lowering drug preparation. Background Art

[0002] Hypertension is a chronic disease characterized by elevated systolic or diastolic blood pressure in systemic arteries. It can cause damage to the heart, brain, kidneys, blood vessels and eyes, and is a key pathogenic factor for heart disease, stroke, renal failure, coronary artery disease and visual impairment. It is considered a major public health problem in the world because of its high prevalence, but low detection rate, treatment rate and cure rate. Currently, most of the antihypertensive drugs used in clinical practice, such as ACEI, calcium channel blockers, AT1 receptor blockers and diuretics, control blood pressure by targeting targets in the renin-angiotensin II-aldosterone system (RAAS). They are usually used in combination, and there are toxic and side effects that some patients cannot tolerate. Therefore, green, efficient and multi-link and multi-target natural active ingredients for hypertension intervention have attracted the attention of researchers. Studies have shown that natural active polysaccharides such as astragalus polysaccharides, red algae polysaccharides and wolfberry polysaccharides have the effect of improving hypertension and its complications.

[0003] Huangda tea is mainly processed from the rough old leaves of summer and autumn tea in western Anhui. Although it is low-cost, it is rich in health-promoting polysaccharides. The applicant's research team found that Huangda tea polysaccharides have multiple pharmacological effects such as anti-oxidation, liver protection, improvement of neuroinflammation, hypoglycemic and lipid-reducing, and regulation of intestinal microecology, but there are no reports on its treatment of hypertension and related target organ damage. In view of this, the applicant evaluated the systolic and diastolic blood pressure, RAAS activity factor, left ventricular mass index, thoracic aorta and kidney tissue pathological observation of two kidneys and one clip (2K1C) hypertensive rats and proved that the new Huangda tea polysaccharide LYTP 2-2 has a good antihypertensive effect. Summary of the invention

[0004] The present invention aims to provide a novel yellow tea polysaccharide and its application in the preparation of antihypertensive drug preparations. The present invention adopts ultrafiltration separation, DEAE-Sepharose Fast Flow ion exchange chromatography and Superdex TM 200 gel filtration chromatography technology was used to prepare the highly active polysaccharide LYTP2-2 from yellow tea with a specific composition. It can lower blood pressure by regulating RAAS and effectively alleviate the damage of target organs of hypertension, and can be used as an ideal candidate drug preparation for lowering blood pressure.

[0005] The novel yellow tea polysaccharide (abbreviated as LYTP2-2) of the present invention has a total sugar content of 89.75%, a monosaccharide composition and a molar ratio of mannose (Man): rhamnose (Rha): galacturonic acid (GalA): glucose (Glc): galactose (Gal): arabinose (Ara) = 1.844: 2.898: 2.4: 29.98: 10.438: 1, and a relative molecular mass of 2.0898×10 4 Da.

[0006] The glycosidic bond composition of the novel yellow tea polysaccharide is 1,5-Araf, 1,4-Galp, 1,4-GalpA, 1,4-Glcp, 1,6-Glcp, 1,6-Galp, 2,4-Rhap, T-Glcp, T-Galp, 3,6-Glcp and 3,6-Manp.

[0007] The preparation method of the novel yellow tea polysaccharide of the present invention comprises the following steps:

[0008] Step 1: grind the yellow tea, pass it through an 80-mesh sieve, add anhydrous ethanol at a solid-liquid ratio of 1:10 (g / mL), soak it in a 60°C water bath for 12 hours, filter it, and dry it to obtain pretreated yellow tea powder;

[0009] Step 2: adding the yellow tea powder obtained in step 1 to pure water at a solid-liquid ratio of 1:20 (g / mL), soaking and softening, 40MPa high-pressure homogenization cycle treatment 3 times, centrifuging, collecting the supernatant and concentrating, adding anhydrous ethanol, stirring thoroughly and standing overnight, centrifuging and collecting the precipitate, re-dissolving in water and freeze-drying to obtain the yellow tea polysaccharide LYTP;

[0010] Step 3: The yellow tea polysaccharide LYTP obtained in step 2 was added to the solution at a retention rate of 5×10 4 Da ultrafiltration membrane for cyclic separation, collecting molecular weight less than 5×10 4 The fractions of Da were concentrated and lyophilized;

[0011] Step 4: Separate and purify the sample obtained in step 3 using a DEAE-Sepharose Fast Flow ion exchange chromatography column, eluting with deionized water and 0.1 mol / L NaCl solution in sequence, collecting the 0.1 mol / L NaCl elution fraction, dialyzing, concentrating, and freeze-drying to obtain purified Camellia sinensis polysaccharide;

[0012] Step 5: The purified yellow tea polysaccharide fraction obtained in step 4 was subjected to Superdex TM The extract was further separated and purified by 200 gel filtration column, eluted with pure water at a flow rate of 0.3 mL / min, collected in separate tubes, and freeze-dried to obtain a new type of yellow tea polysaccharide LYTP 2-2.

[0013] The invention prepares a novel polysaccharide LYTP 2-2 with blood pressure lowering activity from yellow tea for the first time, has a green and safe preparation process, clear ingredients, and has no toxic side effects on the body when taken for a long time.

[0014] The invention discloses an application of the novel yellow tea polysaccharide LYTP 2-2 in the preparation of a blood pressure lowering pharmaceutical preparation.

[0015] The drug preparation has good ACE inhibitory activity, can regulate RAAS to effectively reduce systolic blood pressure, diastolic blood pressure and left ventricular mass index, and improve aortic wall thickening and glomerular shrinkage and increased interspaces, that is, the drug preparation can not only lower blood pressure, but also effectively improve heart, aorta and kidney damage caused by hypertension.

[0016] The novel yellow tea polysaccharide LYTP2-2 of the present invention has clear composition and significant efficacy, and has broad development and application prospects in the research on the preparation of drug preparations for lowering blood pressure and improving target organ damage of hypertension. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 This is the molecular weight distribution diagram of the new yellow tea polysaccharide LYTP 2-2;

[0018] Figure 2 This is the monosaccharide composition diagram of the new yellow tea polysaccharide LYTP 2-2; wherein A is the peak diagram of the standard monosaccharide, and B is the peak diagram of the monosaccharide of LYTP2-2;

[0019] Figure 3 This is the methylation map of the novel yellow tea polysaccharide LYTP 2-2;

[0020] Figure 4 It is the ACE inhibitory activity assay of the novel yellow tea polysaccharide LYTP 2-2;

[0021] Figure 5 This is the effect of the new yellow tea polysaccharide LYTP 2-2 on systolic and diastolic blood pressure in 2K1C hypertensive rats: A is systolic blood pressure, B is diastolic blood pressure;

[0022] Figure 6 This is the effect of the new yellow tea polysaccharide LYTP 2-2 on RAAS levels in 2K1C hypertensive rats: A is the level of renin, B is the level of angiotensin II, and C is the level of aldosterone;

[0023] Figure 7 The effect of the new yellow tea polysaccharide LYTP 2-2 on the pathology of the thoracic aorta in 2K1C hypertensive rats;

[0024] Figure 8 The effect of the new yellow tea polysaccharide LYTP 2-2 on renal tissue pathology in 2K1C hypertensive rats. DETAILED DESCRIPTION

[0025] The preparation of the present invention, the efficacy of lowering blood pressure and improving target organ damage are described below in conjunction with specific examples and drawings. The examples listed are only used to explain the present invention and are not used to limit the scope of protection of the present invention.

[0026] The yellow tea used in the present invention is purchased from Anhui Huoshan County Hengda Tea Co., Ltd.

[0027] Example 1: Preparation of novel yellow tea polysaccharide LYTP2-2

[0028] (1) Extraction of Camellia sinensis polysaccharides

[0029] The yellow tea powder was crushed, passed through an 80-mesh sieve, anhydrous ethanol was added at a solid-liquid ratio of 1:10 (g / mL), soaked in a 60°C water bath for 12 hours, filtered, and dried to obtain pretreated yellow tea powder, pure water was added at a solid-liquid ratio of 1:20 (g / mL), soaked to soften, 40MPa high-pressure homogenization cycle treatment was performed 3 times, centrifuged, the supernatant was collected and concentrated, anhydrous ethanol was added, the mixture was fully stirred and allowed to stand overnight, the precipitate was collected by centrifugation, and it was redissolved in water and freeze-dried to obtain the yellow tea polysaccharide LYTP;

[0030] (2) Ultrafiltration membrane retention

[0031] The above-mentioned yellow tea polysaccharide LYTP was added at a retention rate of 5×10 4 Da ultrafiltration membrane for cyclic separation, collecting molecular weight less than 5×10 4 The fractions of Da were concentrated and lyophilized;

[0032] (3)DEAE-Sepharose Fast Flow and Superdex TM 200 Chromatographic separation and purification

[0033] The sample obtained by ultrafiltration was separated and purified by DEAE-Sepharose Fast Flow ion exchange chromatography column, eluted with deionized water and 0.1 mol / L NaCl solution in sequence, and the 0.1 mol / L NaCl elution fraction was collected, dialyzed, concentrated, lyophilized, and then filtered by Superdex TM The extract was further separated and purified by 200 gel filtration column, eluted with pure water at a flow rate of 0.3 mL / min, collected in separate tubes, and freeze-dried to obtain a new type of yellow tea polysaccharide LYTP2-2. The total sugar content was 89.75% measured by phenol-sulfuric acid method.

[0034] Example 2: Molecular weight, monosaccharide composition and glycosidic bond structure of the novel yellow tea polysaccharide LYTP2-2

[0035] (1) Molecular weight determination:

[0036] LYTP2-2 and dextran standards (T10, T50, T500, T1000, T2000) were prepared into 3 mg / mL solutions with double distilled water and measured using an Agilent high performance liquid chromatography-evaporative light scattering detector. The chromatographic column was TSKGel G6000 PWXL, the mobile phase was deionized water, the carrier gas was N2, the gas flow rate was 2.5 L / min, and the injection volume was 10 μL. The logarithm of the relative molecular mass of the standard (Lg Mw) and the retention time (Rt) were used as the standard curve to measure the molecular weight range of LYTP2-2. The results are shown in the figure. Figure 1 As shown. According to the standard curve of dextran with different molecular weights (lg Mw = -0.2418x + 8.791, R 2 =0.9975), the molecular weight of LYTP 2-2 was calculated to be 2.0898×10 4 Da.

[0037] (2) Monosaccharide composition analysis:

[0038] The monosaccharide composition of the sample after acid hydrolysis of LYTP 2-2 and pre-column PMP (1-phenyl-3-methyl-5-pyrazolone) derivatization was determined by HPLC-DAD (Agilent high performance liquid chromatography-diode array detector). 8 mg of LYTP 2-2 was dissolved in 5 mL of 2 mol / L trifluoroacetic acid. After sealing the tube with nitrogen, it was placed in an oil bath at 110°C for 8 h. Appropriate amounts of methanol were added several times for rotary evaporation until pH 7. 1 mL of deionized water was added for later use. 1 mL of 3 mg / mL standard monosaccharide solution and 1 mL of acid-hydrolyzed LYTP 2-2 solution were added in sequence. NaOH (0.5 mL, 0.3 mol / L) and PMP solution (0.5 mL, 0.5 mol / L) were added. After shaking and mixing, the mixture was reacted in a 70°C water bath for 1 h for PMP pre-column derivatization. Then, it was neutralized with HCl (0.5 mL, 0.3 mol / L) to neutrality, and then extracted with chloroform three times to remove excess PMP. The aqueous phase was filtered through a 0.22 μm filter membrane and detected by HPLC-DAD.

[0039] HPLC-DAD conditions: the chromatographic column was a Zorbox Eclipse XDB-C18 column, the column temperature was 30°C, and the wavelength was 245 nm; the detection mobile phase A was acetonitrile, the mobile phase B was 0.05 mol / L phosphate buffer solution, the gradient elution was 0-60 min, the initial setting was mobile phase A: mobile phase B = 17%: 83%, the final elution ratio was mobile phase A: mobile phase B = 20%: 80%, and the injection volume was 10 uL.

[0040] The results are as follows Figure 2 As shown, A is the peak diagram of standard monosaccharide, and B is the peak diagram of monosaccharide of LYTP 2-2; Figure 2It can be seen that LYTP 2-2 is composed of 6 monosaccharides, and the monosaccharide composition and molar ratio are mannose: rhamnose: galacturonic acid: glucose: galactose: arabinose = 1.844: 2.898: 2.4: 29.98: 10.438: 1.

[0041] (3) Methylation analysis

[0042] LYTP 2-220mg was placed in a 30mL reaction bottle, 6mL of anhydrous DMSO was added, the bottle was sealed with nitrogen, and magnetic stirring was performed for 24h until it was completely dissolved. After the reaction was completed, 240mg of NaOH powder was added, the bottle was sealed with nitrogen, and magnetic stirring was performed for 2h. After adding 4mL of iodomethane, the bottle was sealed with nitrogen, and magnetic stirring was performed for 1h. The addition of iodomethane was repeated 3 times, and finally 6mL of double distilled water was added to terminate the reaction, dialyzed, and concentrated. The fully methylated LYTP2-2 sample was dissolved in 2mL of 2mol / L trifluoroacetic acid, sealed with nitrogen, and placed in an oil bath at 110℃ for 6h. Appropriate amount of methanol was added several times and rotary evaporated until pH 7, and 3mL of deionized water was added for standby use. 60mg of sodium borodeuteride was added to the obtained acid hydrolysis sample, protected from light, sealed with nitrogen, and magnetically stirred for 24h. Cationic resin was added and stirred for 2h. Methanol was added to the obtained solution several times and evaporated under reduced pressure to obtain the reduced polysaccharide LYTP2-2. Finally, 0.5 mL of acetic anhydride and anhydrous pyridine were added to the reduced polysaccharide LYTP 2-2, the bottle was sealed with nitrogen, and the mixture was placed in an oil bath at 100°C for 2 h. After cooling, methanol was added to the rotary evaporator several times to evaporate the mixture, and then water and chloroform were added to extract the mixture. The organic phase was retained and analyzed by gas chromatography-mass spectrometry.

[0043] GC-MS conditions: the chromatographic column was RTX-5MS column, the carrier gas was helium, and the inlet rate was 1 mL / min; the program temperature conditions were: the starting temperature was 50°C, maintained for 7 min; increased to 320°C at 10°C / min, and maintained for 14 min. The ion source temperature was 230°C, the solvent separation was 12 minutes, and the mass spectrum was obtained in the mass-to-charge ratio (m / z) range of 30-580.

[0044] GC-MS test results are as follows Figure 3 , and the results after comparison with the PMAA database are shown in Table 1. The methylation results showed that LYTP 2-2 contained glycosidic bonds such as 2,4-Rhap, 1,5-Araf, T-Glcp, T-Galp, 1,4-Galp, 1,4-GalpA, 1,4-Glcp, 1,6-Glcp, 1,6-Galp, 3,6-Glcp and 3,6-Manp, with a molar percentage of 4.22:2.30:7.60:3.68:9.34:5.50:9.75:39.31:10.41:3.88:3.99 and a branching degree of 23.37%.

[0045] Table 1 LYTP 2-2 methylated sugar alcohol acetyl ester (PMAA) result analysis

[0046]

[0047] Example 3: Determination of ACE inhibitory activity of the novel yellow tea polysaccharide LYTP2-2

[0048] Reagent preparation: borate buffer solution: 6.18 g boric acid and 17.53 g NaCl were dissolved in deionized water, and then the pH was adjusted to 8.3 with 1 mol / L and 0.2 mol / L NaOH solutions, and the volume was fixed to 100 mL for use; the reaction substrate HHL was dissolved in the buffer solution to a concentration of 2.147 g / L; the ACE concentration was 0.05 U / mL; the stop solution HCl concentration was 1 mol / L, and different concentration gradients of yellow tea polysaccharides LYTP and LYTP2-2 and the positive control Teprotide were prepared for use.

[0049] Experimental operation: Use clean centrifuge tubes to set up sample tubes (T), sample background (T0), enzyme reaction tubes (C) and solvent background (C0). Take 200 μL of HHL solution and add it to T, T0, C and C0 reaction tubes. Add 30 μL of polysaccharide and teprotide inhibitor to T and T0 groups, add equal volume of buffer to C and C0 groups, shake and mix, and react at 37°C for 5 min. Then add 100 μL of buffer to C0 and T0 groups, add equal volume of ACE solution to C and T groups, shake and mix, and react at 37°C for 10 min. After that, add 250 μL of HCl to T, T0, C and C0 reaction tubes to terminate the reaction. Add ethyl acetate to extract the reaction product hippuric acid, centrifuge at 5000 rpm for 10 min, take the upper ethyl acetate extract phase, rotary evaporate and concentrate to dry, add 3 mL of deionized water to dissolve the dry product, and measure the absorbance at 228 nm. Set up 3 parallel replicates for each group of samples.

[0050] The calculation formula of ACE inhibitory activity is:

[0051] The results of the test are shown in Figure 4 The new yellow tea polysaccharide LYTP2-2 has good ACE inhibitory activity, which is significantly better than the crude polysaccharide LYTP. When the concentration is 1 mg / mL, the ACE inhibition rate of LYTP 2-2 is 90.2%, and the IC 50 It is 347.78μg / mL.

[0052] Example 4: Effects of the novel yellow tea polysaccharide LYTP2-2 on lowering blood pressure and protecting target organs

[0053] (1) Establishment and grouping of hypertensive rat model

[0054] The experiment used SPF-grade SD male rats with stable blood pressure, provided by the Animal Experiment Center of Anhui Medical University, weighing 300±10g, and the animal license was: SCXK(Zhejiang)2019-0004.

[0055] All rats were randomly divided into the Control group (6 rats) and the Model group after adaptive feeding. The rats in the Model group underwent surgery to establish the 2K1C hypertension model. The initial blood pressure of the rats was measured using the BP-2010 small animal non-invasive blood pressure analysis system. The rats were fasted but not watered overnight before surgery. They were anesthetized with 10% chloral hydrate and fixed prone on a sterile operating table. The left kidney area was depilated. The rats were disinfected with iodine and alcohol in turn at the parallel position of the T13 rib. A 1.5 cm wound was made longitudinally on the left back, and the left renal artery was carefully separated. A sterile vascular clamp with an inner diameter of about 0.2 mm was placed to constrict the blood vessels. Two drops of penicillin were dripped and the wound was sutured. Sodium penicillin was continuously injected into the wound site within one week after surgery to prevent infection. Systolic blood pressure was measured 4 weeks later. The model was considered successful if the blood pressure increased by more than 30 mmHg compared with the initial blood pressure. The rats with successful modeling were randomly divided into 5 groups, with 6 rats in each group, namely hypertension model group (Model), positive control group (Captopril), low-dose LYTP2-2 group (L LYTP2-2), medium-dose LYTP2-2 group (M LYTP2-2) and high-dose LYTP2-2 group (H LYTP2-2). The Captopril group was gavaged with 10 mg / kg of captopril, L LYTP2-2, M LYTP2-2 and HLYTP2-2 were gavaged with 100, 200 and 400 mg / kg of LYTP2-2, respectively, and the Control and Model groups were gavaged with an equal volume of normal saline. The drug administration lasted for 6 weeks. The changes in rat body weight and blood pressure were recorded during the experiment. After the drug administration, the rats were killed, and the serum was taken to determine the level of RAAS activity factors. The left ventricle was isolated and weighed to calculate its ratio to body weight, which was recorded as the left ventricular mass index. The thoracic aorta and kidney sections were isolated for observation, and the data obtained were analyzed for significance using SPSS27.0 software.

[0056] (2) Experimental results

[0057] The clinical manifestation of hypertension is a continuous increase in systolic or diastolic blood pressure at rest. The 2K1C hypertensive rats were induced to have renal artery stenosis by surgery, resulting in a decrease in unilateral renal blood flow. The body activated RAAS to supply blood to the kidneys, which led to an increase in blood pressure. The experiment continuously detected changes in blood pressure, such as Figure 5As shown in the data, the systolic and diastolic blood pressures of rats in the Model group were significantly higher than those in the Control group (P < 0.01), indicating that the animal model of hypertension was successfully established. Both captopril and polysaccharide LYTP2-2 interventions could significantly reduce the systolic and diastolic blood pressures of hypertensive rats (P < 0.01). The captopril group had a significant blood pressure-lowering effect in the early stage, and the decline was weakened in the last two weeks. In comparison, the blood pressure-lowering effect of LYTP 2-2 was more mild and lasting.

[0058] The heart transports blood to the whole body through arteries. Long-term hypertension causes the heart to work continuously under overload. Left ventricular hypertrophy is one of the most obvious manifestations of target organ damage caused by hypertension. Clinically, there is a significant correlation between left ventricular hypertrophy and hypertension. The experiment measured the left ventricular mass (LHWW) and body weight (BW) of rats in each group, and calculated the ratio of the two as the left ventricular mass index (LHWW / BW). The results are shown in Table 2. After 2K1C surgical modeling, the LHWW / BW of rats in the Model group was significantly higher than that in the Control group (P < 0.01). After treatment with LYTP 2-2 polysaccharide, LHWW / BW was significantly reduced (P < 0.01), and the data showed a dose-dependent relationship, indicating that polysaccharide LYTP 2-2 can alleviate left ventricular hypertrophy caused by hypertension.

[0059] Table 2 Effect of LYTP 2-2 on LHWW / BW of rats in each group

[0060]

[0061] RAAS involves multiple hormones and receptors, and plays an inestimable role in blood pressure regulation, vascular disease, heart and kidney function. The main active factors involved are renin, Ang II and aldosterone. The experiment measured the levels of RAAS active factors in the serum of each group of rats. The results are as follows Figure 6 , indicating that the levels of renin, Ang II and aldosterone in the Model group were significantly higher than those in the Control group (P<0.01). After intervention with captopril and LYTP 2-2, the levels of RAAS active factors were significantly reduced (P<0.01), and the downward trend of each LYTP2-2 intervention group showed a dose-dependent relationship. The above results suggest that the new yellow tea polysaccharide LYTP 2-2 reduces blood pressure in rats by regulating RAAS.

[0062] Long-term hypertension can lead to the disorder of endogenous vasodilator / constrictor factor secretion, resulting in inflammatory vascular remodeling and increased aortic thickness. Figure 7The results showed that the surface of the aortic intima of the Model group was irregular and uneven, and the thickness of the vascular wall was uneven. After the intervention of captopril and LYTP 2-2, the thickness of the aorta of the rats was significantly reduced (P < 0.01), and the vascular intima of the H LYTP 2-2 group was more complete, the smooth muscle was more orderly, and the thickness was more uniform. The kidney is another key organ damaged by hypertension. Figure 8 The results showed that the kidney tissue of the Control group was evenly colored and had normal morphology, while the Model group had wrinkled and thickened basement membrane, tubular atrophy, inflammatory cell infiltration and increased glomerular space, while the kidneys of the Captopril group still had obvious glomerular space accompanied by thickened basement membrane and inflammatory cell infiltration. In contrast, the H LYTP 2-2 group had full cytoplasm and intact structure, indicating that LYTP 2-2 can alleviate renal damage in 2K1C hypertensive rats to a certain extent.

[0063] Note: Data values ​​are expressed as mean ± SD. # P<0.05, ## P<0.01 is compared with the blank group. *P<0.05, **P<0.01 is compared with the model group.

Claims

1. A novel yellow tea polysaccharide, characterized in that: The novel yellow tea polysaccharide is abbreviated as LYTP2-2, with a total sugar content of 89.75%, a monosaccharide composition and a molar ratio of mannose: rhamnose: galacturonic acid: glucose: galactose: arabinose = 1.844: 2.898: 2.4: 29.98: 10.438: 1, and a relative molecular mass of 2.0898 × ​​10 4 Da.

2. The novel yellow tea polysaccharide according to claim 1, characterized in that: The glycosidic bond composition of the novel yellow tea polysaccharide includes 1,5-Araf, 1,4-Galp, 1,4-GalpA, 1,4-Glcp, 1,6-Glcp, 1,6-Galp, 2,4-Rhap, T-Glcp, T-Galp, 3,6-Glcp and 3,6-Manp.

3. The method for preparing the novel yellow tea polysaccharide according to claim 1, characterized in that The steps include: Step 1: crush the yellow tea, pass it through an 80-mesh sieve, add anhydrous ethanol, soak it in a 60°C water bath for 12 hours, filter it, and dry it to obtain pretreated yellow tea powder; Step 2: adding pure water to the yellow tea powder obtained in step 1, soaking and softening, high-pressure homogenization, centrifugation, collecting the supernatant and concentrating it, adding anhydrous ethanol, stirring it thoroughly and standing it, centrifuging and collecting the precipitate, re-dissolving it in water and freeze-drying it to obtain the yellow tea polysaccharide LYTP; Step 3: Circulate and separate the yellow tea polysaccharide LYTP obtained in step 2 in an ultrafiltration membrane, collect the components, concentrate them, and freeze-dry them; Step 4: Separate and purify the sample obtained in step 3 using a DEAE-Sepharose Fast Flow ion exchange chromatography column, collect the eluted components, dialyze, concentrate, and freeze-dry to obtain purified Camellia sinensis polysaccharide; Step 5: The purified yellow tea polysaccharide fraction obtained in step 4 was subjected to Superdex TM The product was further separated and purified by 200 gel filtration column, eluted with pure water, collected in separate tubes, and freeze-dried to obtain a new active polysaccharide LYTP 2-2 from yellow tea.

4. The preparation method according to claim 3, characterized in that: In step 1, anhydrous ethanol is added according to a solid-liquid ratio of 1 g:10 mL.

5. The preparation method according to claim 3, characterized in that: In step 2, pure water is added according to a solid-liquid ratio of 1 g:20 mL.

6. The preparation method according to claim 3, characterized in that: In step 2, the 40 MPa high pressure homogenization cycle is performed 3 times.

7. The preparation method according to claim 3, characterized in that: In step 3, the yellow tea polysaccharide LYTP obtained in step 2 was added to the mixture at a retention rate of 5×10 4 Da ultrafiltration membrane for cyclic separation, collecting molecular weight less than 5×10 4 The polysaccharide fraction of Da was concentrated and freeze-dried.

8. The preparation method according to claim 3, characterized in that: In step 4, when a DEAE-Sepharose Fast Flow ion exchange chromatography column is used for separation and purification, deionized water and 0.1 mol / L NaCl solution are used for elution in sequence, and the 0.1 mol / L NaCl elution fraction is collected.

9. Use of the novel yellow tea polysaccharide according to claim 1 in the preparation of antihypertensive drug preparations.

10. Use of the novel yellow tea polysaccharide according to claim 1 in the preparation of a pharmaceutical preparation for improving target organ damage in hypertension.